Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/44264
Title: The liquid biopsy: towards standardisation in preparation for prime time
Authors: Page, Karen
Shaw, Jacqueline A.
Guttery, David S.
First Published: 29-May-2019
Publisher: Elsevier
Citation: Lancet Oncology, 2019, 20(6), pp. 758-760
Abstract: The liquid biopsy holds potential as a more cost-effective, easier, less-invasive method for diagnosing and monitoring cancer, as well as predicting response to many currently available therapies. Circulating tumour cells (CTCs) and circulating free DNA (cfDNA) are currently the most intensely investigated analytes, with some tests already approved in clinical practice. Despite the potential of the liquid biopsy for managing patient therapy, there is currently no widely accepted consensus regarding pre-analytical blood sample handling and technologies used for extracting cfDNA and isolating CTCs, or optimum workflows for their molecular analyses – all of which are required before liquid biopsies can become routinely used in the clinic. Here, we discuss the current status of liquid biopsy testing in patients with solid tumours and the variation in blood sample handling and isolation/extraction methods, focusing on cfDNA and CTCs
DOI Link: 10.1016/S1470-2045(19)30310-9
ISSN: 1470-2045
Links: https://www.sciencedirect.com/science/article/pii/S1470204519303109?via%3Dihub
http://hdl.handle.net/2381/44264
Embargo on file until: 29-Nov-2019
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © Elsevier 2019. After an embargo period this version of the paper will be an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Description: The file associated with this record is under embargo until 6 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
Page et al. LO commentary revision without track changes plain text.pdfPost-review (final submitted author manuscript)583.68 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.